ArticleAmerican journal of translational research2025
Efficacy and prognosis of multimodal angiography-interventions for chronic pulmonary artery stenosis and pulmonary hypertension.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects of multimodal endoluminal interventional technology combined therapy on clinical efficacy, pulmonary vascular resistance (PVR), pulmonary microvessel density (MVD), and long-term prognosis in patients with chronic pulmonary artery stenotic pulmonary hypertension (CPAS-PH).
methodsThis retrospective analysis included 117 CPAS-PH patients (January 2019 - December 2022) who received the combined therapy. They were divided into a control group (n=50) and an observation group (n=67). Baseline data, preoperative and 6-month postoperative PVR, MVD, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), 6-minute walking distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and complications were collected. Kaplan-Meier method was used to analyze 2-year survival, Cox regression to identify independent prognostic factors and nomogram and ROC curve to verify diagnostic efficacy.
resultsThe observation group had a lower 6-month postoperative PVR, LVEDD, NT-proBNP, adverse reaction rate, and 2-year mortality (all P<0.001), but higher MVD, LVEF, 6MWD, and follow-up duration (all P<0.001) than the control group. Multivariate Cox analysis showed PVR≥5.305 WU (HR=4.324, 95% CI: 1.666-11.221, P=0.003), LVEDD≥56.95 mm (HR=3.632, 95% CI: 1.110-11.887, P=0.033) were prognostic factors. Having MVD≥14.5 (HR=0.279, 95% CI: 0.113-0.685, P=0.005) and LVEF≥39.34% (HR=0.093, 95% CI: 0.024-0.354, P=0.001) were protective factors. The nomogram and ROC curve confirmed good diagnostic efficacy.
conclusionMultimodal endoluminal interventional combined therapy effectively reduces PVR, promotes pulmonary microvascular remodeling, and improves cardiac function and exercise tolerance, with favorable long-term prognosis. Postoperative 6-month PVR, MVD, LVEF, and LVEDD are important evaluation indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.